AFP and hepatocellular carcinoma: In summary, our study identified ACSL4 as a novel marker for AFP high subtype HCC and revealed a novel mechanism by which ACSL4 acts as an oncogene in the progression of HCC by mediating the ubiquitination and degradation of c-Myc.